EDGAR Filing Documents for 0001193125-24-011363

Form PREM14A - Preliminary proxy statements relating to merger or acquisition:

SEC Accession No. 0001193125-24-011363

Filing Date

2024-01-19

Accepted

2024-01-19 17:26:35

Documents

Period of Report

2024-01-19

Document Format Files

Seq	Description	Document	Type	Size
1	PREM14A	d35957dprem14a.htm	PREM14A	1371045
2	EX-FILING FEES	d35957dexfilingfees.htm	EX-FILING FEES	20259
3	GRAPHIC	g35957dsp1a.jpg	GRAPHIC	1522
4	GRAPHIC	g35957dsp1b.jpg	GRAPHIC	1224
5	GRAPHIC	g35957dsp1c.jpg	GRAPHIC	2221
6	GRAPHIC	g35957dsp1d.jpg	GRAPHIC	1883
7	GRAPHIC	g35957dsp2.jpg	GRAPHIC	1898
8	GRAPHIC	g35957g17g68.jpg	GRAPHIC	51076
9	GRAPHIC	g35957snap1.jpg	GRAPHIC	2013
10	GRAPHIC	g35957snap2.jpg	GRAPHIC	1054
	Complete submission text file	0001193125-24-011363.txt		1480213

Mailing Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037

Business Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037 (858) 875-2400

Ambrx Biopharma, Inc. (Filer) CIK: 0001990550 (see all company filings)

IRS No.: 932892120 | Fiscal Year End: 1231
Type: PREM14A | Act: 34 | File No.: 000-56600 | Film No.: 24546527
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)